GENEVA, Feb. 28, 2019 /PRNewswire/ -- iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled "Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies" has...
from PR Newswire: https://ift.tt/2VpGaiQ
No comments:
Post a Comment